Two decades of tuberculosis surveillance reveal disease spread, high levels of exposure and mortality, and marked variation in disease progression in wild meerkats

Nadine Müller-Klein¹, Alice Risely¹, Dominik Schmid¹, Marta Manser², Tim Clutton-Brock³, and Simone Sommer¹

¹Universitat Ulm Fachbereich Biologie ²Universitat Zurich Institut fur Evolutionsbiologie und Umweltwissenschaften ³University of Pretoria Mammal Research Institute

May 3, 2022

Abstract

Infections with Tuberculosis (TB)-causing agents of the Mycobacterium tuberculosis complex threaten human, livestock, and wildlife health globally due to the high capacity to cross trans-species boundaries. Tuberculosis is a cryptic disease characterized by prolonged, sometimes lifelong subclinical infections, complicating disease monitoring. Consequently, our understanding of infection risk, disease progression, and mortality across species affected by TB remains limited. The TB agent Mycobacterium suricattae was first recorded in the late 1990s in a wild population of meerkats inhabiting the Kalahari in South Africa and has since spread considerably, becoming a common cause of meerkat mortality. This offers an opportunity to document the epidemiology of naturally spreading TB in a wild population. Here, we synthesize more than 25 years-worth of TB reporting and social interaction data across 3,420 individuals to track disease spread, and quantify rates of TB social exposure, progression, and mortality. We found that most meerkats had been exposed to the pathogen within eight years of first detection in the study area, with exposure reaching up to 95% of the population. Approximately one quarter of exposed individuals progressed to clinical TB stages, followed by physical deterioration and death within a few months. Since emergence, 11.6% of deaths were attributed to TB, although the true toll of TB-related mortality is likely higher. Lastly, we observed marked variation in disease progression among individuals, suggesting inter-individual differences in both TB susceptibility and resistance. Our results highlight that TB prevalence and mortality could be higher than previously reported, particularly in species or populations with complex social group dynamics. Long-term studies, such as the present one, allow us to assess temporal variation in disease prevalence and progression and quantify exposure, which is rarely measured in wildlife. Long-term studies are highly valuable tools to explore disease emergence and ecology, and study host-pathogen co-evolutionary dynamics in general, and its impact on social mammals.

Introduction

Pathogens, particularly those causing emerging diseases, can be a major driver of mortality in wildlife (McCallum, 2008; Fereidouni et al., 2019; Fisher and Garner, 2020), which can be aggravated by changing environments and climate change (Dwyer et al., 2020; Paniw et al., 2022). Cross-sectional studies are often employed to study patterns of pathogen prevalence and transmission, yet their power to assess long-term patterns of pathogen emergence, dynamics and overall pathogen prevalence are limited (Reis et al., 2021). The advantage of longitudinal surveillance studies rest in their ability to identify factors underpinning pathogen transmission, assess the impact of pathogens on individual hosts and populations, and track host-pathogen dynamics (Ryser-Degiorgis, 2013; Walton et al., 2016; Watsa and Wildlife Disease Surveillance Focus Group, 2020). Since long-term projects are difficult to sustain and pathogen monitoring and detection

can be challenging (reviewed in Thomas et al., 2021), such long-term datasets populations are still exceptional in natural (Patterson et al., 2017; McDonald et al., 2018).

Pathogens of the *Mycobacterium tuberculosis* complex (MTC), the causative agents of the disease tuberculosis (TB), are among the most significant emerging pathogens globally (CSFPH, 2019). Generally, *Mycobacterium* infections are chronic, progressive and characterized by prolonged latent (i.e. non-infectious) or subclinical (i.e. without clinical signs but potentially still infectious to others) periods (Houben and Dodd, 2016; CSFPH, 2019; Dwyer et al., 2020; Jolma et al., 2021). If the disease progresses to the development of overt clinical signs, their onset is usually followed by health decline and death (Alexander et al., 2010; Fairbanks et al., 2015). A wide variety of mammals can be infected with MTC bacteria (CSFPH, 2019; Reis et al., 2021), which can easily be transmitted between multiple hosts species, with implications for entire ecosystems (Michel et al., 2006; Hardstaff et al., 2014). Thus, a well-founded understanding of transmission and host-pathogen dynamics is imperative for the development of adequate TB surveillance and management strategies (de Lisle et al., 2002). However, despite intense research efforts in several TB host systems (reviewed in Reis et al., 2021), quantitative data TB exposure, prevalence and progression are still rare for many wildlife species affected by TB.

Meerkats (*Suricata suricatta*) are highly social, cooperatively breeding small carnivores (Clutton-Brock and Manser, 2016) native to southern Africa, a hotspot region for TB in wildlife (Michel et al., 2006; Tanner et al., 2015). Within the Kalahari Meerkat Project (KMP; Clutton-Brock and Manser, 2016), a natural population has been routinely monitored since 1993. First evidence of infections with *Mycobacterium suricattae*, previously believed to be *M. bovis*, were reported in the late 1990s (Drewe, Foote et al., 2009; Parsons et al., 2013). Meerkats have a complex social system characterized by small to medium sized social groups (two to fifty individuals). Reproduction is largely monopolized by dominant breeding pairs (Clutton-Brock and Manser, 2016), which differ from subordinates in physiology (Young et al., 2006; Smyth et al., 2018), social network position(Drewe, 2010), and mortality risk (Cram et al., 2018). Social interactions within and between group are frequent (Clutton-Brock and Manser, 2016), making meerkats an excellent model to investigate pathogen transmission in a social context (Drewe, 2010).

Meerkats are a particularly good model system to investigate TB epidemiology because transmission, progression, and pathology of *M. suricattae* infection mirrors patterns found in other wildlife hosts: Transmission occurs mostly via aerial routes or social interactions (Gallagher and Clifton-Hadley, 2000; Drewe, 2010; Drewe et al., 2011). Infection are initially characterized by long latent or subclinical periods (Drewe et al., 2011; Tomlinson et al., 2013; McDonald et al., 2018), followed by rapid progression to terminal stages upon onset of clinical signs (Alexander et al., 2010; Fairbanks et al., 2015). Typical signs of TB infections, including lymphadenopathy, particularly of submandibular, inguinal and cervical lymph nodes, and physical deterioration 1990s (Drewe, Foote et al., 2009; Parsons et al., 2013)., typically develop ~12 months post infection (Donadio et al., 2022). After progression to clinical TB, meerkats usually become terminally ill with open lesions at affected lymph nodes and die within several months, with no recovery once clinical stage was reached (Patterson et al., 2021). Thus, TB was reported to impact life history and survival, and can lead to group extinctions (Duncan et al., 2021), a pattern aggravated by climate change (Paniw et al., 2022).

Despite some detailed knowledge gained from previous cross-sectional studies regarding TB in meerkats (summarized in Table 1), the dynamics around its spread across the population, and how TB disease manifests over a meerkats' lifetime, remain obscure (see Supplementary Table 1). To fill these gaps, we leverage an extensive long-term dataset with over 25 years of detailed individual data (n=3,420 individuals) to examine TB spread across the population. Specifically, we quantify TB exposure, prevalence of clinical TB, and mortality, provide timelines of typical disease progression in individuals and groups and describe interindividual and temporal variation in TB progression. These findings provide crucial context by which to understand TB epidemiology and ecology.

Materials and Methods

Data used for this study was collected within the KMP on wild meerkats living at the Kuruman River reserve

(26° 580' S, 21°490' E), Northern Cape, South Africa, between the between the 20th of October 1993 and the 29th of December 2020. During this time, several meerkat groups well habituated to human observers were visited multiple times a week and detailed data on individually recognizable individuals collected by trained volunteers and researchers following standardized protocols (for details see Clutton-Brock and Manser, 2016). We included data on all 3,420 individuals encompassed in the study for individual level analyses. As it is common for newly founded meerkat groups to quickly fail (Duncan et al., 2021), we limited the analyses on the group level to 91 groups with a group duration longer than 6 months.

For each individual, we recorded first date as birthdate or first entry date into the population and final date as death date or last observed date as well as available information on clinical signs of TB infection (see Table 2 for definitions on terminology). Individuals can be infectious even prior to the onset of clinical signs (Wilkinson et al., 2000; Donadio et al., 2022), and exposure can vary with social behaviour (Drewe, 2010; Drewe et al., 2011), so exact time of exposure for each individual cannot easily determined. However, individuals with overt signs are likely contributing the most to TB transmission (McDonald et al., 2019), and most individuals were either born into a TB afflicted group or came into contact with TB upon immigration into a TB afflicted group (see below). We consequently chose contact with visibly TB afflicted conspecifics as a conservative, clearly identifiable and relatively accurate estimate for TB exposure, despite some remaining uncertainty regarding individual exposure dates. Individuals were thus classified as TB exposed from the first day of contact to conspecifics with externally visible signs of clinical TB, either by clinical TB emerging in the resident group or by immigrating into a group with visibly infected individuals. Individuals were considered presenting clinical signs from the date they were recorded with TB by observers or displayed clear signs of TB infection (submandibular, inguinal or cervical lumps). If individuals had records of suspected TB, i.e. lumps or swelling with no alternative explanation, and progressed to develop clinical TB, the date of first putative TB symptoms was considered as onset of clinical TB. Clearance of clinical TB has not been recorded in meerkats, so we considered TB infections to be purely progressive with no return to prior states (Patterson et al., 2021). Within KMP, terminally ill individuals were euthanized to curb the spread of the disease (Patterson et al., 2021; Duncan et al., 2021), with infections being confirmed in post-mortem examinations (Patterson et al., 2021). We classified these individuals as having died of TB and included them in our dataset of TB progression (see Table 2), as terminally ill individuals do not recover and are expected to die within a few days or weeks (Patterson et al., 2021). To be conservative in our interpretations, individuals displaying clinical signs at time of death but dying of other or unknown causes (e.g. predation or disappearance) were not considered as having died of TB. At the group level, groups were considered as TB exposed upon the first observation of a clinically ill individual within the group. Groups that did not persist until the end of the study are considered extinct, irrespective of the reason of group termination (group abandoned, disintegrated, etc.).

Based on this data, we calculated time from being exposed to developing clinical signs as proxy of TBsusceptibility, i.e. the risk to become clinically ill upon exposure, and time between clinical signs and death as proxy of resistance, i.e. the capacity of a clinically ill individual to survive despite disease. We also calculated survival (i.e. time from exposure to death) for all exposed individuals (see Donadio et al. 2022, see Table 2). To assess TB exposure and prevalence as well as progression and mortality, we calculated overall and yearly proportion of exposure, clinical infection and TB related death at the group and individual level. Plus, the temporal patterns of TB progression, i.e. TB susceptibility, resistance and survival (definitions see Table 2), were analyzed. Data was retrieved from the KMP database into R using the package RMariaDB (Müller et al., 2020) and processed using the packages tidyverse (Wickham et al., 2019). All analyses were performed in R, version 3.6.3 (R Core Team, 2019). Research for this study was conducted with permission of the ethical committee of Pretoria University and the Northern Cape Conservation Service, South Africa (Permit number: EC031-13, FAUNA 1020-2016).

Results

TB was first recorded in the late 1990s in this population and spread within ~ 8 years amongst all social groups and exposing most individuals to the disease. Between 1993 and 2020, 71% of all individuals were

exposed to TB at some point during their life (n = 2,427/3,420). The proportion of individuals exposed varied markedly between study years (mean \pm SD: 54.8 \pm 38.4%), with no TB exposure recorded prior to 1997. Exposure levels proceeded to rise rapidly until 70 – 95% of individuals were exposed in any given year after 2006 and remained at comparably high levels thereon after. In contrast, clinical signs of the disease increased in frequency less steeply. Between 0 to 29.4% of the study population showed clinical signs (mean \pm SD: 8.6 \pm 9.0%, with 0 to around 6% of individuals dying with confirmed TB (mean \pm SD: 4.2 \pm 4.6%) in any given year (Figure 1, Supplementary Figure 1).

Individuals were most often exposed at birth (75.3%, n = 1827), or upon development of TB signs in their current resident group (19.8%, n = 472). The remaining exposed individuals immigrated into a group already experiencing TB (5.4%, n = 128). Only 22.9% of exposed individuals (n = 555), corresponding to 16.1% of the study population, developed clinical signs of TB within 1.5 years (mean \pm sd: 520 \pm 421 days). The majority of individuals reported with clinical signs were confirmed to have died with or from TB (n = 398), leading to a TB-related mortality rate of 11.6% in the population. This does not account for individuals infected, but not showing overt signs of TB, so it is likely this figure underestimates the real extent of TB related mortality.

We observed marked inter-individual variation in TB progression and outcomes, with time between exposure and first clinical signs ranging from 0 (for index cases in a group) to 2,971 days (Figure 2, Figure 3). The mean duration between exposure and signs was ~1.4 years (mean \pm SD: 520 \pm 421 days, median: 440 days). Individuals survived the onset of clinical signs for up to 2,756 days, although some individuals were recorded with signs only at the time of their death. On average, individuals survived the onset of clinical TB for ~6.6 months (mean \pm SD: 200 \pm 328, median: 70 days), indicative of the rapid progression of TB after development of clinical signs (Figure 2, Figure 3, Supplementary Figure 2). Comparing exposed individuals progressing to clinical TB with exposed individuals never developing TB signs, we found high variation in survival in both groups: Individuals developing TB signs survive between 5 and 3,541 days (mean \pm SD: 720 \pm 529, median = 603 days) past exposure, asymptomatic individuals survived up to 4,123 days (mean \pm SD 432 \pm 485, median = 269 days) past exposure. Asymptomatic individuals thus seemed to die significantly earlier (MWU-test: U = 723844, p < 0.001).

On the group level, we focused on 91 meerkat groups lasting between 196 and 9,235 days (mean \pm SD: 1,513 \pm 1,935 days, median: 660 days). Individuals with clinical TB were present in 62 (68.1%) groups, only eight of which persisted until the end of the study. Additional four groups present at the end of the study had not been in contact with TB. TB prevalence among groups varied between 0% before TB detection in the study and 96% in 2013 and 2016, with an average of 59.5 \pm 33.9% of groups exposed to TB (Figure 1). TB was present in most groups that did not persist (n = 54, 68.4% of extinct groups).

After the first detection of clinical TB, groups persistence varied between only 46 and 6356 days (mean \pm SD: 1,200 \pm 1,352 days, median: 569 days) and notably the two longest surviving groups in our dataset persisted despite being exposed to TB since ~ 17 and 21 years, respectively. Marked variation in group survival past TB exposure is retained when only considering groups that disintegrated after detection of TB, after which these groups survived up to 8,243 days (mean \pm SD: 1,591 \pm 1,858 days, median: 573 days).

Discussion

Using a large long-term dataset including over 3,400 individuals and spanning 27 years, we report the spread of TB in wild meerkats, and quantify the extent of TB exposure, clinical TB prevalence and TB-related mortality. We show that exposure to TB rose to over 50% within approximately eight years after first detection within the population and increased to up to over 90%. Rates of clinical disease and mortality over the same period peaked at around 25% and 6%, respectively, suggesting a degree of resistance to the pathogen. TB prevalence varied strongly between the years, with over one quarter of the population displaying clinical signs in some years. TB prevalence reported this study is comparable with those reported from other well-studied species (~12~% for European badgers (*Meles meles*) to ~32% for red deer (*Cervus elaphus*) and wild boar (*Sus scrofa*), see Reis et al., 2021), both with regard to overall (16.2%) and annual prevalence.

Previous studies, using diagnostic tools on subset of the study population to detect TB reported prevalence between 24% (Drewe, 2010) and up to 82.4% of individuals of exposed groups (Clarke et al., 2016), implying that by using clinical signs, the true extent of Mycobacterium infection prevalence is underestimated.

In line with previous studies, we find TB contributing strongly to meerkat mortality, both on the individual and group level (Patterson et al., 2017; Duncan et al., 2021). At 11.6%, individual TB related mortality is almost twice as high as previously reported in the same population (Patterson et al., 2017), and comparable with estimated annual mortality of mongooses infected with *M. mungi* (Fairbanks et al., 2014). Most individuals (71.7%) with clinical signs were confirmed to have died of or with TB, yet given the irreversible nature of TB progression, the disease was likely a contributing factor in the death of diseased individuals dying of other causes. As many infected individuals likely die before progressing to clinical stages, subclinical infections are known to increase mortality risk (Patterson et al., 2021), and the impact of *Mycobacterium* infections on the population is likely even higher than reported here.

We observe a high extend of variation of TB susceptibility, resistance and progression patterns across the study population. Only ~22% of exposed individuals progress to clinical TB, on average within 1.4. years of exposure. Our findings confirm the generally long latent or subclinical period of *M. suricattae*infections(Drewe, Dean et al., 2009; Donadio et al., 2022), with individuals developing TB signs as long as 8 years past first exposure. As infection occur on average 1 year before the onset of clinical signs (Donadio et al. 2022), most exposed individuals are likely infected for most of the time between exposure and clinical TB manifestation. The rate of individuals not susceptible to TB has been estimated at around 25.8% in a recent study (Donadio et al. 2022), implying that ~ 50% of exposed individuals are infected without displaying overt symptoms. This finding is comparable to results in badgers, where up to 80% of infected individuals do not present visible TB lesions (Gallagher and Clifton-Hadley, 2000).

After onset of clinical TB, meerkats in our study died on average within ~ 6.6 months, confirming the rapid progression to terminal stages reported by previous studies of the same population (Patterson et al., 2021; Donadio et al., 2022). This pattern of prolonged subclinical or latent infection with rapid progression upon onset of clinical signs is a common feature of wildlife TB (Alexander et al., 2010; Tomlinson et al., 2013; Spickler, 2019). Individuals survived for up to 7.5 years post first TB signs, suggesting factors facilitating natural TB resistance. The capacity of some individuals to survive TB for a long period is another common feature of wildlife MTC pathogen infections (Ezenwa et al., 2010; Tomlinson et al., 2013). Paradoxically, individuals eventually developing TB signs die at older ages than individuals that never proceed to clinical TB stages, a phenomenon most likely attributable to the long latent period compared to meerkat life expectancy. Baseline mortality rates in meerkats are high, with subordinates suffering increased mortality risk upon evictions (Cram et al., 2018), so while KMP meerkats can live up to ~12 years, median life expectancy is only 2.3 years (Drewe, 2009), making death of infected individuals prior to clinical manifestation of TB a likely occurrence.

The origin of M. suricattae in the study population and when it first emerged is currently unclear. Furthermore, whether meerkats are the original host, or the pathogen was transmitted from another, yet unknown reservoir species, is not clear to date (Alexander et al., 2010; Parsons et al., 2013). While the disease was probably present in the study population from the beginning of data recording, and exposure as well as prevalence are likely underestimated in the first years of the long-term project, clinical TB is a highly conspicuous and easily recognizable disease, allowing the conclusion that the rapid increase in detected cases after the late 1990s is reflective of increased disease prevalence and transmission rather than an artifact of observation bias. This conclusion is also supported by the observation that both bovine and non-bovine TB seems to become increasingly prevalent in southern Africa (Michel et al., 2006; Alexander et al., 2010; Tanner et al., 2015; Parsons et al., 2019). Originally, inter-species transmission of M. bovis was suspected to cause the TB outbreaks in meerkats (Drewe, Dean et al., 2009; Drewe, Foote et al., 2009) before identification of M. suricattae (Parsons et al., 2013, 2019), which is now considered to be endemic in meerkats (Patterson et al., 2022).

The mechanisms underlying this increased TB prevalence and transmission are likely complex and multi-

faceted, and their detailed discussion is beyond the scope of this study. However, based on our findings and previous research, we can identify factors that likely contributed to the rapid spread of TB, both inherent to the host-pathogen system and external factors, and discuss the implication of the establishment of TB within the population. Even though clinical TB is highly contagious, there are no obvious behavioural defenses against TB transmission in meerkats: Banded mongooses (*Mungos mungo*), which are closely related to meerkats, apparently do not avoid TB affected conspecifics (Fairbanks et al., 2015), and there is no evidence for avoidance behaviour in meerkats to date. Additionally, subclinically infected individuals have been shown to shed *M. suricattae* via their faces (Donadio et al., 2022) and thus might be infectious and facilitate transmission, as observed in badgers (Graham et al., 2013; Tomlinson et al., 2013). Both factors could favour spread of TB within a susceptible population. Both within and between group social contact patterns are well established as contributing factors to TB transmission in social mammals (Drewe, 2010; Weber et al., 2013), and in meerkats in particular, migrating males have been implicated to transmit TB between groups (Duncan et al., 2021; Paniw et al., 2022). Consequently, long subclinical infection periods, limitations in behaviourally avoiding TB exposure, and frequent social contacts can facilitate rapid TB transmission within a population based on high levels of exposure.

Transmission can further be facilitated by increased susceptibility to a pathogen. Adverse climate conditions have been suggested to exacerbate the negative effects of TB on individuals and populations (Dwyer et al., 2020; Paniw et al., 2022), potentially indicative of such increased susceptibility to TB of individuals affected by environmental stressors. In the study population, above average temperatures increasingly occurred after the early 2000s and correlate with clinical TB occurrence (Paniw et al., 2022). Both, adverse climate conditions and clinical TB reduce meerkat survival and can lead to group failure, particularly of small groups (Duncan et al., 2021; Paniw et al., 2022), which can lead to higher social mobility, as remnant individuals form new groups or immigrate into other groups. With immigration increasing the risk of TB transmission into previously TB-free groups, these may become more vulnerable to adverse environmental conditions and group extinction once individuals progress to clinical TB and the group suffers from TB related mortality (Duncan et al., 2021; Paniw et al., 2022). Thus, the negative effects of climate change and TB emergence can enforce each other, facilitating TB transmission throughout the study population and affecting population dynamics. Potentially, the effect of M. suricattae infections transcends meerkats and has implications for entire eco-systems, based on the high inter-species transmissibility of MTC pathogens and a wide TB presence in South African mammals (Hlokwe et al., 2014; Clarke et al., 2016; Parsons et al., 2019). Predation is one of the main causes of meerkat mortality (~25%, NMK, unpublished data), so meerkat predators are likely to become exposed to M. suricattae via infected prey, potentially facilitating transmission via ingestion. This possibility highlights the need for detailed and systematic surveillance studies to understand the impact of TB on not only single species, but entire ecosystems.

Our study is based on purely observational data and thus not suitable to investigate determinants of TB susceptibility, resistance and progression. Individuals differ strongly in how they are affected by TB, and the high level of exposed but never clinically ill individuals is suggestive of non-susceptible individuals within the population. Future studies should investigate the impact of hosts immune genetics and responses (Ezenwa and Jolles, 2015; Ezenwa et al., 2021; Jolma et al., 2021; Marjamäki et al., 2021) in explaining the variation in TB susceptibility, resistance and progression. Furthermore, assessing for effects of pathogen-mediated selection on meerkat population genomics and risk of co-infections will be highly informative furthering our understanding of the effect of TB on meerkat ecology and evolution.

Acknowledgements

We thank Dr. Pablo Santos for his invaluable support during an early stage of the project and Dr. Stuart Patterson for his mindful comments on the manuscript. We are grateful to the Kalahari Research Trust and the Kalahari Meerkat Project for access to facilities and habituated animals in the Kuruman River Reserve, South Africa. This paper has relied on records of individual identities and/or life histories maintained by the Kalahari Meerkat Project, which has been supported by the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (Research Grant Nos 294494 and 742808 to T.H. Clutton-Brock since 1/7/2012), the Human Frontier Science Program (funding reference RGP0051/2017), the University of Zurich, the Swiss National Science Foundation and the Mammal Research Institute at the University of Pretoria, South Africa. Research for this study was conducted with permission of the ethical committee of Pretoria University and the Northern Cape Conservation Service, South Africa (Permit number: EC031-13, FAUNA 1020-2016). The study is funded by the German Research Foundation to S. Sommer (DFG SO 428/15-1).

Conflict of interest statement

The authors declare no conflicts of interest

References

Alexander, K.A., P.N. Laver, A.L. Michel, M. Williams, P.D. van Helden, R.M. Warren, and N.C.G. van Pittius, 2010: Novel *Mycobacterium tuberculosis* complex pathogen, *M. mungi*. *Emerg. Infect. Dis.* **16**, 1296.

CFSPH, 2019: Zoonotic tuberculosis in mammals, including bovine and caprine tuberculosis. 1–20. cfsph.iastate.edu/diseaseinfo/factsheets/.

Clarke, C., P. Van Helden, M. Miller, and S. Parsons, 2016: Animal-adapted members of the *Mycobacterium tuberculosis* complex endemic to the southern African subregion. J. S. Afr. Vet. Assoc.87, 1–7, DOI: 10.4102/jsava.v87i1.1322.

Clutton-Brock, T.H., and M. Manser, 2016: Meerkats: Cooperative breeding in the Kalahari. *Coop. Breed. Vertebr. Stud. Ecol. Evol. Behav.* 294–317, DOI: 10.1017/CBO9781107338357.018.

Cram, D.L., P. Monaghan, R. Gillespie, B. Dantzer, C. Duncan, H. Spence-Jones, and T. Clutton-Brock, 2018: Rank-related contrasts in longevity arise from extra-group excursions not delayed senescence in a cooperative mammal. *Curr. Biol.* **28**, 2934-2939.e4, DOI: 10.1016/j.cub.2018.07.021.

de Lisle, G.W., R.G. Bengis, S.M. Schmitt, and D.J. O;Brien, 2002: Tuberculosis in free-ranging wildlife: detection, diagnosis and management. *Rev. Sci. Tech.* **21**, 317–333.

Donadio, J., A. Risely, N. Müller-Klein, K. Wilhelm, T. Clutton-Brock, M.B. Manser, and S. Sommer, 2022: Characterizing tuberculosis progression in wild meerkats (*Suricata suricatta*) from fecal samples and clinical signs. J. Wildl. Dis. DOI: 10.7589/JWD-D-21-00063.

Drewe, J.A., 2009: Social networks and infectious disease transmission: epidemiology of tuberculosis in wild meerkats. PhD thesis, University of Cambridge.

Drewe, J.A., 2010: Who infects whom? Social networks and tuberculosis transmission in wild meerkats. *Proc.* R. Soc. B Biol. Sci.277, 633–642, DOI: 10.1098/rspb.2009.1775.

Drewe, J.A., G.S. Dean, A.L. Michel, G.P. Pearce, K.P. Lyashchenko, R. Greenwald, and G.P. Pearce, 2009: Accuracy of three diagnostic tests for determining *Mycobacterium bovis* infection status in live-sampled wild meerkats (*Suricata suricatta*). J. Vet. Diagnostic Investig. **21**, 31–39, DOI: 10.1177/104063870902100226.

Drewe, J.A., K.T.D. Eames, J.R. Madden, and G.P. Pearce, 2011: Integrating contact network structure into tuberculosis epidemiology in meerkats in South Africa: implications for control. *Prev. Vet. Med.* **101**, 113–120, DOI: 10.1016/j.prevetmed.2011.05.006.

Drewe, J.A., A.K. Foote, R.L. Sutcliffe, and G.P. Pearce, 2009: Pathology of *Mycobacterium bovis* infection in wild meerkats (*Suricata suricatta*). J. Comp. Pathol. **140**, 12–24, DOI: 10.1016/j.jcpa.2008.09.004.

Duncan, C., M.B. Manser, and T. Clutton-Brock, 2021: Decline and fall: The causes of group failure in cooperatively breeding meerkats. *Ecol. Evol.* **11**, 14459–14474, DOI: https://doi.org/10.1002/ece3.7655.

Dwyer, R.A., C. Witte, P. Buss, W.J. Goosen, and M. Miller, 2020: Epidemiology of tuberculosis in multi-host wildlife systems: implications for black (*Diceros bicornis*) and white (*Ceratotherium simum*) rhinoceros. *Front. Vet. Sci.* 887.

Ezenwa, V.O., S.A. Budischak, P. Buss, M. Seguel, G. Luikart, A.E. Jolles, and K. Sakamoto, 2021: Natural resistance to worms exacerbates bovine tuberculosis severity independently of worm coinfection. *Proc. Natl. Acad. Sci.* **118**, 1–9, DOI: 10.1073/pnas.2015080118.

Ezenwa, V.O., R.S. Etienne, G. Luikart, A. Beja-Pereira, and A.E. Jolles, 2010: Hidden consequences of living in a wormy world: Nematode-induced immune suppression facilitates tuberculosis invasion in African buffalo. *Am. Nat.* **176**, 613–624, DOI: 10.1086/656496.

Fairbanks, B.M., D.M. Hawley, and K.A. Alexander, 2014: The impact of health status on dispersal behavior in banded mongooses (*Mungos mungo*). *Ecohealth* **11**, 258–262.

Fairbanks, B.M., D.M. Hawley, and K.A. Alexander, 2015: No evidence for avoidance of visibly diseased conspecifics in the highly social banded mongoose (*Mungos mungo*). *Behav. Ecol. Sociobiol.***69**, 371–381, DOI: 10.1007/s00265-014-1849-x.

Fereidouni, S., G.L. Freimanis, M. Orynbayev, P. Ribeca, J. Flannery, D.P. King, S. Zuther, M. Beer, D. Höper, and A. Kydyrmanov, 2019: Mass die-off of saiga antelopes, Kazakhstan, 2015. *Emerg. Infect. Dis.*25, 1169.

Fisher, M.C., and T.W.J. Garner, 2020: Chytrid fungi and global amphibian declines. *Nat. Rev. Microbiol.* **18**, 332–343, DOI: 10.1038/s41579-020-0335-x.

Gallagher, J., and R.S. Clifton-Hadley, 2000: Tuberculosis in badgers; a review of the disease and its significance for other animals. *Res. Vet. Sci.* **69**, 203–217.

Graham, J., G.C. Smith, R.J. Delahay, T. Bailey, R.A. McDonald, and D. Hodgson, 2013: Multi-state modelling reveals sex-dependent transmission, progression and severity of tuberculosis in wild badgers. *Epidemiol. Infect.* **141**, 1429–1436, DOI: 10.1017/S0950268812003019.

Hardstaff, J.L., G. Marion, M.R. Hutchings, and P.C.L. White, 2014: Evaluating the tuberculosis hazard posed to cattle from wildlife across Europe. *Res. Vet. Sci.* **97**, S86–S93, DOI: https://doi.org/10.1016/j.rvsc.2013.12.002.

Hlokwe, T.M., P. van Helden, and A.L. Michel, 2014: Evidence of increasing intra and inter-species transmission of *Mycobacterium bovis* in South Africa: Are we losing the battle? *Prev. Vet. Med.***115**, 10–17, DOI: 10.1016/j.prevetmed.2014.03.011.

Houben, R.M.G.J., and P.J. Dodd, 2016: The global burden of latent tuberculosis infection: A re-estimation using mathematical modelling. *PLoS Med.* **13**, 1–13, DOI: 10.1371/journal.pmed.1002152.

Jolma, E.R., R.J. Delahay, F. Smith, and J.A. Drewe, 2021: Serologic responses correlate with current but not future bacterial shedding in badgers naturally infected with *Mycobacterium bovis*. *Transbound. Emerg. Dis.* **n/a**, DOI: https://doi.org/10.1111/tbed.14181.

Madden, J.R., J.A. Drewe, G.P. Pearce, and T.H. Clutton-Brock, 2011: The social network structure of a wild meerkat population: 3. Position of individuals within networks. *Behav. Ecol. Sociobiol.* **65**, 1857–1871, DOI: 10.1007/s00265-011-1194-2.

Marjamäki, P.H., H.L. Dugdale, R. Delahay, R.A. McDonald, and A.J. Wilson, 2021: Genetic, social and maternal contributions to *Mycobacterium bovis* infection status in European badgers (*Meles meles*). J. Evol. Biol. **34**, 695–709.

McCallum, H., 2008: Tasmanian devil facial tumour disease: lessons for conservation biology. *Trends Ecol. Evol.* **23**, 631–637.

McDonald, Jenni L., A. Robertson, and M.J. Silk, 2018: Wildlife disease ecology from the individual to the population: Insights from a long-term study of a naturally infected European badger population. J. Anim. Ecol. 87, 101–112, DOI: 10.1111/1365-2656.12743.

McDonald, JENNI L, R.J. Delahay, and R.A. McDonald, 2019: Bovine tuberculosis in badgers: Sociality, infection and demography in a social mammal, pp. 342–367. In: Wilson, Kenneth, Andy Fenton, and Dan Tompkins (eds), Wildlife Disease Ecology: Linking Theory to Data and Application. Cambridge: Cambridge University Press.

Michel, A.L., R.G. Bengis, D.F. Keet, M. Hofmeyr, L.M. de Klerk, P.C. Cross, A.E. Jolles, D. Cooper, I.J. Whyte, P. Buss, and J. Godfroid, 2006: Wildlife tuberculosis in South African conservation areas: Implications and challenges. *Vet. Microbiol.* **112**, 91–100.

Müller, K., J. Ooms, D. James, H. DebRoy, Saikat Wickham, and J. Horner, 2020: RMariaDB: Database Interface and "MariaDB" Driver. R package version 1.0.10.

Paniw, M., C. Duncan, F. Groenewoud, J.A. Drewe, M. Manser, A. Ozgul, and T. Clutton-Brock, 2022: Higher temperature extremes exacerbate negative disease effects in a social mammal. *Nat. Clim. Chang.* DOI: 10.1038/s41558-022-01284-x.

Parsons, S.D.C., J.A. Drewe, N.C. ey van Pittius, R.M. Warren, and P.D. van Helden, 2013: Novel cause of tuberculosis in meerkats, South Africa. *Emerg. Infect. Dis.* **19**, 2004, DOI: 10.3201/eid1912.130268.

Parsons, S.D.C., M.A. Miller, and P.D. van Helden, 2019: The *Mycobacterium tuberculosis* complex in Africa, pp. 73–86. In: Tuberculosis in animals: an African perspective. Springer.

Patterson, S., J.A. Drewe, D.U. Pfeiffer, and T.H. Clutton-Brock, 2017: Social and environmental factors affect tuberculosis related mortality in wild meerkats. *J. Anim. Ecol.* **86**, 442–450, DOI: 10.1111/1365-2656.12649.

Patterson, S.J., C. Clarke, T.H. Clutton-Brock, M.A. Miller, S.D.C. Parsons, D.U. Pfeiffer, T. Vergne, and J.A. Drewe, 2021: Combining analytical approaches and multiple sources of information to improve interpretation of diagnostic test results for tuberculosis in wild meerkats. *Animals* **11**, DOI: 10.3390/ani11123453.

Patterson, S.J., T.H. Clutton-Brock, D.U. Pfeiffer, and J.A. Drewe, 2022: Trait-based vaccination of individual meerkats (*Suricata suricatta*) against tuberculosis provides evidence to support targeted disease control. *Animals* **12**, DOI: 10.3390/ani12020192.

R Core Team, 2019: R: A language and environment for statistical computing. . Vienna, Austria: Foundation for Statistical Computing.

Reis, A.C., B. Ramos, A.C. Pereira, and M. V Cunha, 2021: The hard numbers of tuberculosis epidemiology in wildlife: A meta-regression and systematic review. *Transbound. Emerg. Dis.* **68**, 3257–3276.

Ryser-Degiorgis, M.-P., 2013: Wildlife health investigations: needs, challenges and recommendations. *BMC Vet. Res.* **9**, 223, DOI: 10.1186/1746-6148-9-223.

Smyth, K.N., N.M. Caruso, C.S. Davies, T.H. Clutton-Brock, and C.M. Drea, 2018: Social and endocrine correlates of immune function in meerkats: Implications for the immunocompetence handicap hypothesis. *R. Soc. Open Sci.* 5, DOI: 10.1098/rsos.180435.

Tanner, M., O. Inlameia, A. Michel, G. Maxlhuza, A. Pondja, J. Fafetine, B. Macucule, M. Zacarias, J. Manguele, and I.C. Moiane, 2015: Bovine Tuberculosis and Brucellosis in Cattle and African Buffalo in the Limpopo National Park, Mozambique. *Transbound. Emerg. Dis.***62**, 632–638.

Thomas, J., A. Balseiro, C. Gortazar, and M.A. Risalde, 2021: Diagnosis of tuberculosis in wildlife: a systematic review. *Vet. Res.*52, 1–23.

Tomlinson, A.J., M.A. Chambers, G.J. Wilson, R.A. Mcdonald, and R.J. Delahay, 2013: Sex-Related heterogeneity in the life-history correlates of *Mycobacterium bovis* infection in European Badgers (*Meles meles*). *Transbound. Emerg. Dis.* **60**, 37–45, DOI: 10.1111/tbed.12097.

Walton, L., G. Marion, R.S. Davidson, P.C.L. White, L.A. Smith, D. Gavier-Widen, L. Yon, D. Hannant, and M.R. Hutchings, 2016: The ecology of wildlife disease surveillance: demographic and prevalence fluctuations undermine surveillance. J. Appl. Ecol. 53, 1460–1469, DOI: https://doi.org/10.1111/1365-2664.12671.

Watsa, M., and W. Disease Surveillance Focus Group, 2020: Rigorous wildlife disease surveillance. *Science* (80-.). **369**, 145–147, DOI: 10.1126/science.abc0017.

Weber, N., S.P. Carter, S.R.X.X. Dall, R.J. Delahay, J.L. McDonald, S. Bearhop, and R.A. McDonald, 2013: Badger social networks correlate with tuberculosis infection. *Curr. Biol.* **23**, R915–R916, DOI: https://doi.org/10.1016/j.cub.2013.09.011.

Wickham, H., M. Averick, J. Bryan, W. Chang, L.D. McGowan, R. Francois, G. Grolemund, A. Hayes, L. Henry, and J. Hester, 2019: Welcome to the Tidyverse. *J. open source Softw.* **4**, 1686.

Wilkinson, D., G.C. Smith, R.J. Delahay, L.M. Rogers, C.L. Cheeseman, and R.S. Clifton-Hadley, 2000: The effects of bovine tuberculosis (*Mycobacterium bovis*) on mortality in a badger (*Meles meles*) population in England. J. Zool. **250**, 389–395.

Young, A.J., A.A. Carlson, S.L. Monfort, A.F. Russell, N.C. Bennett, and T. Clutton-Brock, 2006: Stress and the suppression of subordinate reproduction in cooperatively breeding meerkats. *Proc. Natl. Acad. Sci. U. S. A.* **103**, 12005–12010, DOI: 10.1073/pnas.0510038103.

Tables and Figures

Table 1. Previous studies on *Mycobacterium* infections in wild meerkats in the Kalahari, South Africa with highlighted key findings.

Reference	Study type	Data collection	Sample size	Key findings
Alexander et al., 2002	Pathogen identification	1998/1999	N = 20	Immigration of TB afflicted
Drewe, Foote et al., 2009	TB pathology	2005 - 2007	N = 57	Detailed pathology of 52 in
Drewe, Dean et al., 2009b	TB detection assay validation	2005 - 2007	N = 240	Combining multiple diagno
Drewe 2010	TB transmission study	2006/2007	N = 110	TB transmission is impacted
Drewe et al., 2011	TB transmission study	2006/2007	N = 134	TB transmission impacted
Parsons et al., 2013	Molecular description of TB	Not reported	N = 4	Identification and description
Clarke et al., 2016	TB detection assay validation	2014/2015	N = 108	IP-10 release assay as viabl
Patterson et al., 2017	TB transmission study	2001 - 2015	N = 2388	TB infection risk increased
Patterson et al., 2021	TB detection assay validation	2014 - 2016	N = 268	TB infections double morta
Patterson et al., 2022	Intervention study	2014 - 2016	N = 135	Vaccinations of high contac
Duncan et al., 2021	TB effect on demography	1993 - 2019	N = 98 groups	TB linked to group failure,
Paniw et al., 2022	TB effect on demography	1997 - 2018	N = 2691	Impact of adverse climate e
Donadio et al., 2022	TB detection assay validation	1998 - 2018	N = 66	Detection of <i>M. suricattae</i>
Present study	Quantification of TB	1993 - 2020	N = 3420	High levels of TB exposure

Table 2. TB related terminology and definitions of life-history parameters used in the present study.

Term	Definition
TB classification	TB classification
Exposure	Meerkats are classified as exposed to TB if they a) are cohabiting with an individual expressing c
Clinical TB signs	Meerkats are classified as clinical TB cases from the first day they express clear signs of M . surice
Group TB	Past or present cases of clinical TB within the respective group. Based on the long subclinical ph

Term	Definition
Susceptibility	The time taken for an exposed meerkat to develop clinical signs of TB, used as proxy of individua
Resistance	The time-period between development of clinical signs and death, representing the capability of a
Survival	Time period between exposure to TB and death, irrespective of development of clinical disease.
TB death	Individual was euthanized with terminal TB infection or infection was confirmed by post-mortem
Life history parameters	Life history parameters
First date	First recorded date for the respective individual, i.e. birthdate for individuals born into the study
Last date	Last recorded date for the respective individual, i.e. date of death or last record of the individual
Group start	First date of records for the respective group
Group end	Recorded date of group failure, irrespective of the nature of this failure (group split, group extinct

Figure 1



Figure 1: Patterns of TB exposure, prevalence of clinical signs and TB-related death over 27 years of research at the Kalahari Meerkat Project (South Africa) illustrating the inter-annual variation and development of TB prevalence within the study population. Absolute numbers (barplots) and proportion of A) meerkat groups and B) individuals of the study population being not exposed yet (green), exposed (blue), displaying clinical signs of TB (orange) or dying with confirmed TB (red). Means \pm sd of each measure were calculated in 3-months increments.

Figure 2



Figure 2: Life trajectories of meerkats that developed clinical TB (n = 555). For each individual, respective first (birth or entering into the study population) and last (death or disappearance) dates, as well as transitions between TB states are shown. Individuals were on average exposed to TB for 1.4 years before the onset of clinical signs and survived on average until 6.6 months after developing clinical TB. Individuals are sorted by birth date.

Figure 3



Figure 3: Meerkat life expectancy. Variation in life expectancy of meerkats with known final age (i.e. age at death or disappearance, n = 3,113), based on their TB status. Points indicate the mean, vertical lines the standard deviation.

Supplementary Material

Supplementary Table 1. Summary of information available on *Mycobacterium infections* in wild meerkats in the Kalahari, South Africa.

TB prevalence Reference	TB prevalence Exposure	TB prevalence Clinical TB	TB prevalence Confirmed TB in-	TB prevalence Mortality	TB prevalence TB de- tection	TB prevalence Sample size	TB prevalence Data collec- tion	TB prevale: Comm
Alexander et al., 2002	100%	100%	N = 1	100%	Signs, PM, MC	N = 20	1998/1999	Trackin TB spread through 1 group follow- ing immi- gration of positive individu
Drewe, Foote et al., 2009	n.r.	91.2%	91.2%	91.2%	PM, MC	N = 57	2005 - 2007	Detailed pathol- ogy of 52 indi- viduals eutha- nized for TB (5 indi- viduals as control
Drewe, Dean et al., 2009	46.7%*	n.r.	13.2%	n.r.	MC, IRT	N = 240	2005 - 2007	Exposu deter- mined by immune reaction assay
Drewe 2010	n.r.	n.r.	9% to 33%	n.r.	MC, IRT	N = 110	2006/2007	TB trans- mission study, preva- lence reporte in 3 months periods

Drewe et al., 2011	30%*	n.r.	n.r.	n.r.	MC, IRT	N = 134	2006/2007	Exposu deter- mined by immune reaction assay, longitu- dinal testing of 37
Clarke et al., 2016	n.r.	n.r.	34.7%	n.r.	IRT	N=108	2014/2015	individ TB detecte by immuna reaction assay, 24.7% to 82.4% depend ing on esti- mated expo- sure
Patterson et al., 2017	n.r.	6%	6%	6%	Signs	N = 2388	2001 - 2015	risk TB defined as clinical signs followed by TB related euthan
Patterson et al., 2021	n.r.	17.5%	8.95%	11.1%	PM, MC, IRT, PCR	N = 268	2014 - 2016	TB de- tection assay validati
Patterson et al., 2022	n.r.	n.r.	n.r.	19%	MC, IRT	N = 135	2014 - 2016	Interve study
Duncan et al., 2021	n.r.	63% (group level)	n.r.	63% (group level)	Signs	N = 98 groups	1993 - 2019	TB effect o demogr

Donadio et al., 2022	100%	56.1%	60.6%	27.3%	Signs, PCR	$\mathbf{N} = 66$	1998 - 2018	TB detecti assay validat individ selected likely 7 exposu and sig TB infectio 53% sig + PCF 7.6% P only
present	71%	16.1%	n.r.	11.6%	Signs	N =	1993 -	TB
B) TB	B) TB	B) TB	B) TB	B) TB	B) TB	3420 B) TB	2020 B) TB	R) TR
progression Reference	progression Exposure – infec- tion	progression Exposure - signs	progression Infection - signs	progression Signs - death	progression TB de- tection	progression Sample size	progression Data collec- tion	progres Comm
Alexander et al., 2002	n.r.	$\tilde{6}$ and 14 m	n.r.	n.r.	Signs, PM, MC	N = 20	1998/1999	See above
Drewe 2010	10m (1.5- 25.3m)	n.r.	n.r.		MC, IRT	N = 110	2006/2007	See above
Drewe et al., 2011	12.6m	n.r.	n.r.	8.1m (infec- tion to death)	MC, IRT	N = 134 (37 longitu- dinal testing)	2006/2007	See above
Patterson et al., 2017	n.r.	n.r.	n.r.	< 6 months	Signs, TB related euthanasia	N = 2388	2001 - 2015	See above
Duncan et al., 2021	n.r.	n.r.	n.r.	10 months (group level)	Signs	N = 98 groups	1993 - 2019	See above
Donadio et al., 2022	$\begin{array}{c} 14.0 \pm \\ 10.8 \mathrm{m} \end{array}$	n.r.	$\begin{array}{c} 11.5 \ \pm \\ 6.9 \mathrm{m} \end{array}$	$\begin{array}{c} 5.3 \pm \\ 5.7 \mathrm{m} \end{array}$	$\frac{\text{Signs}}{\text{PCR}}$	N = 66	1998 - 2018	See above
Present study	n.r.	$17.1 \pm 13.8 {\rm m}$	n.r.	$6.6 \pm 10.8 { m m}$	Signs	$\begin{array}{l} \mathrm{N} = \\ 3420 \end{array}$	1993 - 2020	See above

PM:P	Abbreviation	ns:Abbreviatic	ons:Abbreviatio	ons:Abbreviatio	ons:Abbreviatio	ons:Abbreviatio	ons:Abbreviatio	ons:Abbreviatio	ons:Abbrev
postpostpostpostpostpostpostpostpostmortemmortemmortemmortemmortemmortemmortemmortemmortemexami-exami	PM:	PM:	PM:	PM:	PM:	PM:	PM:	PM:	PM:
mortemmortemmortemmortemmortemmortemmortemmortemmortemmortemexami-exami-exami-exami-exami-exami-exami-exami-exami-nation; <td< td=""><td>post</td><td>post</td><td>post</td><td>post</td><td>post</td><td>post</td><td>post</td><td>post</td><td>post</td></td<>	post	post	post	post	post	post	post	post	post
exami- nation;exami- nation;exami- nation;exami- nation;exami- nation;exami- nation;exami- nation;exami- nation;exami- nation;exami- nation;exami- nation;exami- nation;exami- nation;exami- nation;exami- nation;exami- nation;exami- nation;exami- nation;exami- signs:sign:sign:sign:	mortem	mortem	mortem	mortem	mortem	mortem	mortem	mortem	morten
nation;signs ofsigns ofsign	exami-	exami-	exami-	exami-	exami-	exami-	exami-	exami-	exami-
	nation;	nation;	nation;	nation;	nation;	nation;	nation;	nation;	nation;
clinical signs of sig	signs:	signs:	signs:	signs:	signs:	signs:	signs:	signs:	signs:
signs of TB;	clinical	clinical	clinical	clinical	clinical	clinical	clinical	clinical	clinical
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	signs of	signs of	signs of	signs of	signs of	signs of	signs of	signs of	signs of
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	TB;	ТВ;	$\widetilde{\mathrm{TB}};$	$\widetilde{\mathrm{TB}};$	$\widetilde{\mathrm{TB}};$	TB;	$\widetilde{\mathrm{TB}};$	$\widetilde{\mathrm{TB}};$	TB;
My-My-My-My-My-My-My-My-My-My-My-My-My-cobacte- <td>MC:</td> <td>MC:</td> <td>MC:</td> <td>MC:</td> <td>MC:</td> <td>MC:</td> <td>MC:</td> <td>MC:</td> <td>MC:</td>	MC:	MC:	MC:	MC:	MC:	MC:	MC:	MC:	MC:
cobacte-cobacte	My-	My-	My-	My-	My-	My-	My-	My-	My-
rial rial rial rial rial rial rial rial	cobacte-	cobacte-	cobacte-	cobacte-	cobacte-	cobacte-	cobacte-	cobacte-	cobacte
cultures;	rial	rial	rial	rial	rial	rial	rial	rial	rial
IRT:InmuneI	cultures;	cultures;	cultures;	cultures;	cultures;	cultures;	cultures;	cultures;	culture
ImmuneImmuneImmuneImmuneImmuneImmuneImmuneImmuneImmuneImmuneresponser	IRT:	IRT:	IRT:	IRT:	IRT:	IRT:	IRT:	IRT:	IRT:
responserespons	Immune	Immune	Immune	Immune	Immune	Immune	Immune	Immune	Immun
tests;test	response	response	response	response	response	response	response	response	respons
n.r.: notn.r.: not	tests;	tests;	tests;	tests;	tests;	tests;	tests;	tests;	tests;
reportedreporte	n.r.: not	n.r.: not	n.r.: not	n.r.: not	n.r.: not	n.r.: not	n.r.: not	n.r.: not	n.r.: no
*Posi-*Posi	reported	reported	reported	reported	reported	reported	reported	reported	reporte
tive intive intive intive intive intive intive intive intive inimmuneimmuneimmuneimmuneimmuneimmuneimmuneimmuneimmunereactionreactionreactionreactionreactionreactionreactionreactionassays <t< td=""><td>*Posi-</td><td>*Posi-</td><td>*Posi-</td><td>*Posi-</td><td>*Posi-</td><td>*Posi-</td><td>*Posi-</td><td>*Posi-</td><td>*Posi-</td></t<>	*Posi-	*Posi-	*Posi-	*Posi-	*Posi-	*Posi-	*Posi-	*Posi-	*Posi-
immuneimmuneimmuneimmuneimmuneimmuneimmuneimmuneimmunereactionreactionreactionreactionreactionreactionreactionreactionassaysassaysassaysassaysassaysassaysassaysassaysassaysassaysFor allFor allFor allFor allFor allFor allFor allFor allFor allstudies,studies,studies,studies,studies,studies,studies,studies,studies,dura-dura-dura-dura-dura-dura-dura-dura-dura-tionstionstionstionstionstionstionstionstionsreportedreportedreportedreportedreportedreportedreportedreportedin daysin daysin daysin daysin daysin daysin daysin dayswerewerewerewerewerewerewereweretrans-trans-trans-trans-trans-trans-trans-formedformedformedformedformedformedformedformedintointointointointointointointointononthsmonthsmonthsmonthsmonthsmonthsmonthsmonthsmonthsto allowto allowto allowto allowto allowto a	tive in	tive in	tive in	tive in	tive in	tive in	tive in	tive in	tive in
reactionreactionreactionreactionreactionreactionreactionreactionreactionassays </td <td>immune</td> <td>immune</td> <td>immune</td> <td>immune</td> <td>immune</td> <td>immune</td> <td>immune</td> <td>immune</td> <td>immune</td>	immune	immune	immune	immune	immune	immune	immune	immune	immune
assaysassay	reaction	reaction	reaction	reaction	reaction	reaction	reaction	reaction	reaction
For allFor allfulles <thfulles< th="">fu</thfulles<>	assays	assays	assays	assays	assays	assays	assays	assays	assays
studies,studies	For all	For all	For all	For all	For all	For all	For all	For all	For all
dura-	studies,	studies,	studies,	studies,	studies,	studies,	studies,	studies,	studies.
tionstionstionstionstionstionstionstionstionstionstionsreported<	dura-	dura-	dura-	dura-	dura-	dura-	dura-	dura-	dura-
reportedin daysin days <th< td=""><td>tions</td><td>tions</td><td>tions</td><td>tions</td><td>tions</td><td>tions</td><td>tions</td><td>tions</td><td>tions</td></th<>	tions	tions	tions	tions	tions	tions	tions	tions	tions
in daysin daysin daysin daysin daysin daysin daysin daysin dayswerewerewerewerewerewerewerewerewerewereweretrans-trans-trans-trans-trans-trans-trans-trans-trans-formedformedformedformedformedformedformedformedformedintointointointointointointointointomonthsmonthsmonthsmonthsmonthsmonthsmonthsmonthsmonthsto allowto allowto allowto allowto allowto allowto allowto allowto alloweasiereasiereasiereasiereasiereasiereasiercompar-compar-compar-isonisonisonisonisonisonisonisonisonisonisonbetweenbetweenbetweenbetweenbetweenbetweenbetweenbetweenbetweenbetween	reported	reported	reported	reported	reported	reported	reported	reported	reporte
werewe	in days	in days	in days	in days	in days	in days	in days	in days	in days
trans-trans-trans-trans-trans-trans-trans-trans-trans-formed	were	were	were	were	were	were	were	were	were
formedformedformedformedformedformedformedformedformedformedintointointointointointointointointointointointomonths	trans-	trans-	trans-	trans-	trans-	trans-	trans-	trans-	trans-
intointointointointointointointomonths<	formed	formed	formed	formed	formed	formed	formed	formed	formed
monthsmonthsmonthsmonthsmonthsmonthsmonthsmonthsmonthsto allowto allowto allowto allowto allowto allowto allowto allowto alloweasiereasiereasiereasiereasiereasiereasiereasiereasiereasiercompar-compar-compar-compar-compar-compar-compar-compar-compar-isonisonisonisonisonisonisonisonisonisonbetweenbetweenbetweenbetweenbetweenbetweenbetweenbetweenbetweenstudiesstudiesstudiesstudiesstudiesstudiesstudiesstudiesstudies	into	into	into	into	into	into	into	into	into
to allowto allowto allowto allowto allowto allowto allowto allowto alloweasier </td <td>months</td> <td>months</td> <td>months</td> <td>months</td> <td>months</td> <td>months</td> <td>months</td> <td>months</td> <td>months</td>	months	months	months	months	months	months	months	months	months
easiereasiereasiereasiereasiereasiereasiereasiereasiercompar- <t< td=""><td>to allow</td><td>to allow</td><td>to allow</td><td>to allow</td><td>to allow</td><td>to allow</td><td>to allow</td><td>to allow</td><td>to allow</td></t<>	to allow	to allow	to allow	to allow	to allow	to allow	to allow	to allow	to allow
compar-compar-compar-compar-compar-compar-compar-compar-compar-compar-isonisonisonisonisonisonisonisonisonisonbetweenbetweenbetweenbetweenbetweenbetweenbetweenbetweenbetweenstudiesstudiesstudiesstudiesstudiesstudiesstudiesstudies	easier	easier	easier	easier	easier	easier	easier	easier	easier
ison ison ison ison ison ison ison ison	compar-	compar-	compar-	compar-	compar-	compar-	compar-	compar-	compar
between betwee	ison	ison	ison	ison	ison	ison	ison	ison	ison
studies studies studies studies studies studies studies studies	between	between	between	between	between	between	between	between	between
	studies	studies	studies	studies	studies	studies	studies	studies	studies

Supplementary Figure 1



Supplementary Figure 1: Patterns of TB exposure, prevalence of clinical signs and TB-related death over 27 years of research at the Kalahari Meerkat Project (South Africa) illustrating the inter-annual variation and development of TB prevalence within the study population. The numbers of A) study groups and B) study individuals of the study population being not exposed yet (green), exposed (blue), displaying clinical signs of TB (orange) or dying with confirmed TB (red). Means \pm sd of each measure were calculated in 3-months increments.

Supplementary Figure 2



Supplementary Figure 2: Life trajectories of meerkats (n = 3,420). For each individual, respective first (birth or entering into the study population) and last (death or disappearance) dates, as well as transitions between TB states are shown. Individuals were on average exposed to TB for 1.4 years before the onset of clinical signs and survived on average until 6.6 months after developing clinical TB. Individuals are sorted by birth date.



